Last reviewed · How we verify

Levobupivacaine 0.1% + Sufentanil 0.2µg/ml

Dr Madeleine Wilwerth · Phase 3 active Small molecule

Levobupivacaine 0.1% + Sufentanil 0.2µg/ml is a Local anesthetic + opioid combination Small molecule drug developed by Dr Madeleine Wilwerth. It is currently in Phase 3 development for Regional anesthesia and analgesia (epidural administration), Perioperative pain management. Also known as: control group.

Levobupivacaine blocks sodium channels to provide local anesthesia, while sufentanil activates opioid receptors to provide analgesia, together delivering regional anesthesia and pain relief.

Levobupivacaine blocks sodium channels to provide local anesthesia, while sufentanil activates opioid receptors to provide analgesia, together delivering regional anesthesia and pain relief. Used for Regional anesthesia and analgesia (epidural administration), Perioperative pain management.

At a glance

Generic nameLevobupivacaine 0.1% + Sufentanil 0.2µg/ml
Also known ascontrol group
SponsorDr Madeleine Wilwerth
Drug classLocal anesthetic + opioid combination
TargetVoltage-gated sodium channels (levobupivacaine); mu opioid receptor (sufentanil)
ModalitySmall molecule
Therapeutic areaAnesthesia / Pain Management
PhasePhase 3

Mechanism of action

Levobupivacaine is a long-acting local anesthetic that inhibits sodium influx in nerve fibers, preventing action potential propagation and sensory/motor blockade in a localized region. Sufentanil is a potent synthetic opioid agonist at mu opioid receptors that enhances analgesia. This combination is used for epidural or regional anesthesia to provide both sensory blockade and opioid-mediated pain relief.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Levobupivacaine 0.1% + Sufentanil 0.2µg/ml

What is Levobupivacaine 0.1% + Sufentanil 0.2µg/ml?

Levobupivacaine 0.1% + Sufentanil 0.2µg/ml is a Local anesthetic + opioid combination drug developed by Dr Madeleine Wilwerth, indicated for Regional anesthesia and analgesia (epidural administration), Perioperative pain management.

How does Levobupivacaine 0.1% + Sufentanil 0.2µg/ml work?

Levobupivacaine blocks sodium channels to provide local anesthesia, while sufentanil activates opioid receptors to provide analgesia, together delivering regional anesthesia and pain relief.

What is Levobupivacaine 0.1% + Sufentanil 0.2µg/ml used for?

Levobupivacaine 0.1% + Sufentanil 0.2µg/ml is indicated for Regional anesthesia and analgesia (epidural administration), Perioperative pain management.

Who makes Levobupivacaine 0.1% + Sufentanil 0.2µg/ml?

Levobupivacaine 0.1% + Sufentanil 0.2µg/ml is developed by Dr Madeleine Wilwerth (see full Dr Madeleine Wilwerth pipeline at /company/dr-madeleine-wilwerth).

Is Levobupivacaine 0.1% + Sufentanil 0.2µg/ml also known as anything else?

Levobupivacaine 0.1% + Sufentanil 0.2µg/ml is also known as control group.

What drug class is Levobupivacaine 0.1% + Sufentanil 0.2µg/ml in?

Levobupivacaine 0.1% + Sufentanil 0.2µg/ml belongs to the Local anesthetic + opioid combination class. See all Local anesthetic + opioid combination drugs at /class/local-anesthetic-opioid-combination.

What development phase is Levobupivacaine 0.1% + Sufentanil 0.2µg/ml in?

Levobupivacaine 0.1% + Sufentanil 0.2µg/ml is in Phase 3.

What are the side effects of Levobupivacaine 0.1% + Sufentanil 0.2µg/ml?

Common side effects of Levobupivacaine 0.1% + Sufentanil 0.2µg/ml include Hypotension, Bradycardia, Nausea, Pruritus, Respiratory depression, Urinary retention.

What does Levobupivacaine 0.1% + Sufentanil 0.2µg/ml target?

Levobupivacaine 0.1% + Sufentanil 0.2µg/ml targets Voltage-gated sodium channels (levobupivacaine); mu opioid receptor (sufentanil) and is a Local anesthetic + opioid combination.

Related